When trans‐arterial chemoembolization therapy eradicates all or majority of the tumor vasculature, it creates a short therapeutic window for oxygen enhancement therapy to inhibit hypoxia‐induced VEGF secretion and thus prevent tumor revascularization, improving long‐term clinical response. The gene discussed is VEGFA; the disease is neoplasm.